Bioassays & Screening
Aurelia Bioscience Ltd is a pre-clinical contract research company focusing on supplying biochemical and cell-based compound screening expertise to small to medium enterprise (SME) companies, universities, research institutes, charities and large pharmaceuticals companies.
Our vision is to be recognised by our clients, partners and peers as a centre of excellence for these activities. Underlying this is a desire to continue to contribute to the discovery of new therapeutic compounds for unmet medical need.
Our team has extensive experience of developing and screening compounds in biochemical assays for a range of targets including but not limited to proteases, kinases, and phosphodiesterase enzymes and protein:protein interaction.
Cell based assays are of key importance at a number of stages in the drug discovery process. Being able to examine the interaction between your target and compounds in a cellular context is of great advantage.
Our scientists have in-depth experience of label-free technology applied to cell-based assays gained over the past 6 years using Coring EPIC, Perkin Elmer EnSpire and SRU Bioscience Bind instruments.
Scientists at Aurelia have decades of experience between them working in real-world drug discovery projects utilising FLIPR, FMAT, EPIC label free and Envision-based assays in both biochemical and cell-based formats
A comprehensive service to drug discovery clients including assay development, reagent testing and scale-up, proof of technology concept and validation, phenotypic screening and consultancy.
The members of Aurelia Bioscience have been involved in the design and development of many drug discovery projects incorporating complex biology and implementing a suite of assays designed to identify “active” compounds and improve their biological properties.
Acting as an intermediary between instrument and reagent manufacturers and prospective clients we can provide an expert lab-based environment for the validation of new technologies.